# reload+after+2024-01-21 23:43:16.885592
address1§One Corporate Drive
address2§2nd Floor
city§South San Francisco
state§CA
zip§94080
country§United States
phone§800 466 6059
website§https://www.aligos.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
fullTimeEmployees§68
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Lawrence M. Blatt MBA, Ph.D.', 'age': 61, 'title': 'CEO & Chairman of the Board', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 832725, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Julian A. Symons DPHIL', 'age': 62, 'title': 'Executive VP & Chief Scientific Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 618661, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lesley Ann Calhoun CPA', 'age': 57, 'title': 'Executive VP & CFO', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lucinda Y. Quan J.D.', 'age': 51, 'title': 'Executive VP, Chief Business Officer & General Counsel', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 444263, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Kristina  Engeseth', 'title': 'VP and Head of People & Culture', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthew W. McClure M.D.', 'age': 51, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sushmita M. Chanda DABT, Ph.D.', 'age': 57, 'title': 'Executive Vice President of Translational Safety Sciences', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David B. Smith Ph.D.', 'title': 'Executive VP & Head of Chemical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Tse-I  Lin Ph.D.', 'title': 'VP of Early Compound Development & Belgian Site Head', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.194
priceToSalesTrailing12Months§3.2469683
currency§USD
dateShortInterest§1702598400
forwardEps§-0.96
exchange§NMS
quoteType§EQUITY
shortName§Aligos Therapeutics, Inc.
longName§Aligos Therapeutics, Inc.
firstTradeDateEpochUtc§1602855000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bbc2c389-779c-3f10-ac5a-f071b0904bd5
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§1.0
targetMeanPrice§3.67
targetMedianPrice§3.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§3.135
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
